With a continuing interest on heteropolycyclic structures which may show biological activities, we synthesized new tricyclic derivatives in which the pyridopyrazine skeleton is fused with pyrazine 7 and 8, B, n = 1. However, the initial design of obtaining also the cyclohomologous structure B (n = 2) produced instead a pyranopyridopyrazine derivative 11. Thus during the attempt to prepare a pyridodiazepine intermediate, beside a very small amount of the desired product 10, the pyridopyrazine 9 was obtained. The latter compound reacted with chloroacetyl chloride/chloroketene to give 4‐carbethoxy‐10‐(chloroacetyl)‐5,10‐dihydro‐5‐methyl‐2H‐pyrano[2,3‐b]pyrido[2,3‐e]pyrazin‐2‐one (11). In studying the behavior of this derivative, compounds 12–14 were obtained. Compounds 4b,c, 5a,b, 7, 8, 9 and 14 have been submitted to preliminary pharmacological screening as CNS depressant agents.